Quick Answer
Edwards Lifesciences Corp reported R&D Expense of $1.08 billion for fiscal year 2025.
Edwards Lifesciences Corp R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $1.08B | +2.5% |
| 2024 | $1.05B | +9.4% |
| 2023 | $962.90M | +14.1% |
| 2022 | $843.60M | -6.6% |
| 2021 | $903.10M | +18.7% |
| 2020 | $760.70M | +1.1% |
| 2019 | $752.70M | +21.0% |
| 2018 | $622.20M | +12.6% |
| 2017 | $552.60M | +25.0% |
| 2016 | $442.20M | +15.5% |
| 2015 | $382.90M | +10.5% |
| 2014 | $346.50M | +7.3% |
| 2013 | $323.00M | +10.9% |
| 2012 | $291.30M | +18.3% |
| 2011 | $246.30M | +20.5% |
| 2010 | $204.40M | +16.5% |
| 2009 | $175.50M | +26.1% |
| 2008 | $139.20M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $280.70M | +10.8% | +1.6% |
| June 30, 2025 | $276.20M | +1.6% | +8.5% |
| March 31, 2025 | $254.60M | -0.8% | +0.5% |
| September 30, 2024 | $253.40M | +4.4% | -6.8% |
| June 30, 2024 | $271.80M | +11.5% | +5.9% |
| March 31, 2024 | $256.70M | -1.7% | +5.7% |
| September 30, 2023 | $242.80M | +3.9% | -0.4% |
| June 30, 2023 | $243.70M | -2.8% | -6.7% |
- Edwards Lifesciences Corp showed an increase of +2.5% in R&D Expense compared to the prior fiscal year.
- Over the 2008–2025 period, Edwards Lifesciences Corp’s r&d expense has grown by 675.3% (from $139.20 million to $1.08 billion).
- The most recent figure is from Edwards Lifesciences Corp’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 25, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: